B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome
Wednesday, October 19, 2011 - 18:30
in Health & Medicine
Chronic fatigue syndrome (CFS) may be alleviated by the anti-cancer drug Rituximab, suggesting that the source of the disease could lie in the immune system, according to a new study published Oct. 19 in the online journal PLoS ONE. Uncertainty about the cause of CFS, which is characterized by extreme, unexplained exhaustion, among other symptoms, has led to much debate, but the authors of this recent study believe they may have found the answer.